-

01:10:02 PM

ABT Stock News

ABT - Abbott Laboratories

05/27/22 12:05 PM

NYSE : ABT

Diandra “Fu” Debrosse Zimmermann Becomes First Black Woman Ever Appointed to Lead a Multidistrict Litigation with Co-Lead Counsel Selection in Baby Formula MDL

Debrosse Zimmermann was appointed to the role in the massive products liability MDL, In Re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation, against two of the world’ s largest manufacturers of infant formula, Abbott Laboratories and Mead Johnson. Debrosse Zimmermann, managing partner of national plaintiff’ s law firm,...

RHEA-AI

negative

05/24/22 5:11 PM

NYSE : ABT

Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need

Abbott to release limited quantities of EleCare ® branded specialty formulas Product will be released immediately free of charge to children in need Parents and caregivers in urgent need should contact their healthcare professionals or Abbott at +1-800-881-0876 for additional information Abbott

RHEA-AI

neutral

05/19/22 9:15 AM

NYSE : ABT

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies One-year

RHEA-AI

neutral

05/16/22 4:22 PM

NYSE : ABT

Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility

After FDA approval, Abbott could restart the site within two weeks; from the time of restart it would take six to eight weeks before product is available on shelves Abbott will continue to import formula from FDA-registered facility in Ireland to help alleviate near-term supply shortage CDC

RHEA-AI

neutral

05/11/22 9:00 AM

NYSE : ABT

partnershipclinical trial

Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

New partnership will provide physician training to drive improved diversity in clinical trials Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists Provides opportunities for underrepresented

RHEA-AI

neutral

05/04/22 9:00 AM

NYSE : ABT

Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise

Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity™ m system, which provides fast results in high volumes – detecting four infections simultaneously Test provides a critically important tool as people return to regular STI testing; a pause in testing during the

RHEA-AI

neutral

04/29/22 4:35 PM

NYSE : ABT

Abbott to Release Metabolic Nutrition Formulas

Metabolic nutrition formulas previously on hold will be released free of charge to patients, in coordination with healthcare professionals based on need and on a case-by-case basis The lots being released were not included in the February recall and are now being released at the request of the U.S.

RHEA-AI

neutral

04/29/22 9:00 AM

NYSE : ABT

Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months

Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experiencing an improved quality of life The catheter is part of Abbott's suite of electrophysiology solutions designed to improve procedures to address cardiac

RHEA-AI

neutral

04/28/22 9:00 AM

NYSE : ABT

Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., Abbott's steerable sheath offers precise and flexible placement when used with the company's Amplatzer

RHEA-AI

neutral

04/28/22 7:00 AM

NYSE : ABT

New Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes

Meta-analysis of 75 real-world studies found that Abbott's FreeStyle Libre system is associated with significant reductions in glycated hemoglobin (HbA1c) at three months 1 Reductions in HbA1c followed a similar pattern in people with both type 1 and type 2 diabetes and were sustained for up to 24

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next